---
title: 'Outcomes with intensive treatment for acute myeloid leukemia: an analysis
  of two decades of data from the HARMONY Alliance'
date: '2024-11-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39506894/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241108190013&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Since 2017, targeted therapies combined with conventional intensive chemotherapy
  have started to improve outcome of patients with acute myeloid leukemia (AML). However,
  even before these innovations outcomes with intensive chemotherapy have improved,
  which has not yet been extensively studied. Thus, we used a large pan-European multicenter
  dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over
  two decades. In 5359 AML patients, we compared the impact of ...
disable_comments: true
---
Since 2017, targeted therapies combined with conventional intensive chemotherapy have started to improve outcome of patients with acute myeloid leukemia (AML). However, even before these innovations outcomes with intensive chemotherapy have improved, which has not yet been extensively studied. Thus, we used a large pan-European multicenter dataset of the HARMONY Alliance to evaluate treatment-time dependent outcomes over two decades. In 5359 AML patients, we compared the impact of ...